Thomas Eldridge Stinchcombe

Journal article Lung Cancer · January 2026 PURPOSE: Next-generation anaplastic lymphoma kinase (ALK)-targeting tyrosine kinase inhibitors (TKIs) are standard first-line (1L) treatments for ALK+ advanced non-small cell lung cancer (aNSCLC). Treatments differ in systemic and central nervous system (C ... Full text Link to item Cite

Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.

Journal article Lung Cancer · September 2021 OBJECTIVES: Veliparib is a potent poly(ADP)-ribose polymerase (PARP) 1 and 2 inhibitor that impedes repair of DNA damage induced by cytotoxic and radiation therapies. This phase 1 study evaluated veliparib in combination with chemoradiotherapy in patients ... Full text Link to item Cite

Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.

Journal article Cancer Treat Res Commun · 2019 INTRODUCTION: Retrospective studies have evaluated the approach of stereotactic radiotherapy (SRT) to address oligoprogression in patients with EGFR mutant NSCLC on TKI therapy, it has never been prospectively studied. MATERIALS AND METHODS: We treated 25 ... Full text Link to item Cite